Search
Apatorsen
go.drugbank.com/drugs/DB06094InvestigationalApatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers
Virginiamycin S1
go.drugbank.com/drugs/DB04805ExperimentalIt is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. … One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others.
Matuzumab
go.drugbank.com/drugs/DB05101InvestigationalMatuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.
Neovastat
go.drugbank.com/drugs/DB05387InvestigationalNeovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases … It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870Experimentalgrowth factor (VEGF), basic fibroblast growth factor (bFGF), as well as other pro-angiogenic growth factors. … The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial
Elafin
go.drugbank.com/drugs/DB05161InvestigationalElafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or … The excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study.
Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalIt is developed by MedImmune for the treatment of Allergic Rhinitis. … Bertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.
Synonyms: IMMUNOGLOBULIN G4, ANTI-(HUMAN EOTAXIN 1) (HUMAN MONOCLONAL CAT-213 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CAT-213 .KAPPA.-CHAIN, DIMERXamoterol
go.drugbank.com/drugs/DB13781ApprovedXamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. … It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
SNS01-T
go.drugbank.com/drugs/DB17302InvestigationalSNS01-T is a gene therapy nanoparticle. … It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Pralnacasan
go.drugbank.com/drugs/DB04875ExperimentalPralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).